Non-small cell lung cancer (NSCLC) presents a complex and diverse disease, exhibiting variations at individuals’ cellular and histological levels. This complexity gives rise to different subtypes and genetic mutations, posing challenges for accurate diagnosis and effective treatment. Nevertheless, continuous progress in medical research and therapies is continually shaping the landscape of NSCLC diagnosis and management. The treatment of NSCLC has undergone significant advancements in recent years, especially with the emergence of targeted therapies that have shown remarkable efficacy in patients with actionable mutations. This has ushered in the era of personalized medicine in NSCLC treatment, with improvements in molecular and immunohistochemical techniques contributing to enhanced progression-free survival. This review focuses on the latest progress, challenges, and future directions in developing targeted therapies for NSCLC, including tyrosine kinase inhibitors (TKIs), DNA-damaging agents, immunotherapy regimens, natural drug therapy, and nanobodies. Furthermore, recent randomized studies have demonstrated enhanced overall survival in patients receiving different targeted and natural drug therapies.
非小细胞肺癌（NSCLC）是一种复杂且异质性的疾病，在个体细胞和组织学层面均表现出显著差异。这种复杂性导致了不同亚型和基因突变的存在，为精准诊断和有效治疗带来了挑战。然而，医学研究和治疗手段的持续进步，正不断重塑着NSCLC的诊断与管理格局。近年来，NSCLC的治疗取得了显著进展，尤其是靶向疗法的出现，在具有可作用突变的患者中显示出卓越疗效，从而开启了NSCLC个体化治疗的新时代。分子检测与免疫组化技术的改进，共同促进了患者无进展生存期的延长。本综述重点探讨了NSCLC靶向治疗领域的最新进展、面临的挑战及未来方向，涵盖酪氨酸激酶抑制剂、DNA损伤剂、免疫治疗方案、天然药物疗法及纳米抗体等。此外，近期随机研究显示，接受不同靶向及天然药物治疗的患者总生存期有所改善。
Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer
肿瘤(癌症)患者之家